On May 26, 2023, EF Hutton reiterated its Hold coverage recommendation for Apexigen (NASDAQ:APGN), according to Fintel.
Positive Price Forecast
As of May 11, 2023, the average one-year price target for Apexigen is 4.79, which represents an increase of 787.78% from its latest reported closing price of 0.54. The forecasts range from a low of 1.41 to a high of $8.40.
For a leaderboard of companies with the largest price target upside, visit Fintel.
Projections for Apexigen
The projected annual revenue for Apexigen is 0MM, while the projected annual non-GAAP EPS is -1.54.
Fund Sentiment and Shareholders
There are 33 funds or institutions reporting positions in Apexigen, indicating an increase of 4 owner(s) or 13.79% in the last quarter. The average portfolio weight of all funds dedicated to APGN is 0.35%, which represents an increase of 143.72%. Total shares owned by institutions increased in the last three months by 6.03% to 3,542K shares. The put/call ratio of APGN is 0.26, indicating a bullish outlook.
The top shareholders of Apexigen are Decheng Capital Management III, Yu Fan, Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, and Cvi Holdings.
For key filings related to the company, visit Fintel.
The opinions expressed in this article are solely those of the author and do not necessarily reflect the views of Nasdaq, Inc.
